$MBRX
Moleculin Biotech, Inc.

2016 Q2 Form 10-Q Financial Statement

#000114420416108589 Filed on June 16, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2016 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $620.0K $310.0K
YoY Change
% of Gross Profit
Research & Development $105.0K $15.00K
YoY Change
% of Gross Profit
Depreciation & Amortization $1.000K $0.00
YoY Change
% of Gross Profit
Operating Expenses $724.0K $321.0K
YoY Change
Operating Profit -$724.0K -$321.0K
YoY Change
Interest Expense $15.00K $11.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$740.0K -$330.0K
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$739.0K -$332.0K
YoY Change
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$493.3K -$138.7K
COMMON SHARES
Basic Shares Outstanding 11.23M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.240M $260.0K
YoY Change
Cash & Equivalents $7.245M $260.0K
Short-Term Investments
Other Short-Term Assets $320.0K
YoY Change
Inventory
Prepaid Expenses $315.1K
Receivables $30.00K
Other Receivables $0.00
Total Short-Term Assets $7.560M $290.0K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $7.168K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $11.67M -$337.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $7.560M $290.0K
Total Long-Term Assets $11.67M -$337.00
Total Assets $19.23M $289.7K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $970.0K $360.0K
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $430.0K $620.0K
YoY Change
Total Short-Term Liabilities $1.403M $980.0K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $600.0K $0.00
YoY Change
Other Long-Term Liabilities $600.0K
YoY Change
Total Long-Term Liabilities $600.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.403M $980.0K
Total Long-Term Liabilities $600.0K $0.00
Total Liabilities $2.003M $978.0K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$2.076M -$1.081M
YoY Change
Common Stock $19.31M $395.3K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $17.23M -$688.3K
YoY Change
Total Liabilities & Shareholders Equity $19.23M $289.7K
YoY Change

Cashflow Statement

Concept 2016 Q2 2016 Q1
OPERATING ACTIVITIES
Net Income -$739.0K -$332.0K
YoY Change
Depreciation, Depletion And Amortization $1.000K $0.00
YoY Change
Cash From Operating Activities -$1.360M -$290.0K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $30.00K -$30.00K
YoY Change
Cash From Investing Activities $30.00K -$30.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $386.5K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.310M 550.0K
YoY Change
NET CHANGE
Cash From Operating Activities -1.360M -290.0K
Cash From Investing Activities 30.00K -30.00K
Cash From Financing Activities 8.310M 550.0K
Net Change In Cash 6.980M 230.0K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$1.360M -$290.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 dei Document Type
DocumentType
10-Q
CY2016Q1 dei Amendment Flag
AmendmentFlag
false
CY2016Q1 dei Document Period End Date
DocumentPeriodEndDate
2016-03-31
CY2016Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
322790 USD
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q1 dei Entity Registrant Name
EntityRegistrantName
Moleculin Biotech, Inc.
CY2016Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001659617
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28091 USD
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
-688340 USD
CY2016Q1 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
30000 USD
CY2015Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
0 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-744699 USD
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
289663 USD
CY2016Q1 us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
30000 USD
CY2016Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11228403 shares
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-332241 USD
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2101 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28091 USD
CY2016Q1 mbrx Working Capital Deficit
WorkingCapitalDeficit
688340 USD
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
40213 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-289927 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
259663 USD
CY2016Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q1 dei Trading Symbol
TradingSymbol
MBRX
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-30000 USD
CY2016Q1 us-gaap Assets
Assets
289663 USD
CY2015Q4 us-gaap Assets
Assets
28091 USD
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
386499 USD
CY2016Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
165000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
551499 USD
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
231572 USD
CY2016Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
615000 USD
CY2015Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
450000 USD
CY2016Q1 us-gaap Liabilities
Liabilities
978003 USD
CY2015Q4 us-gaap Liabilities
Liabilities
772790 USD
CY2016Q1 us-gaap Interest Paid
InterestPaid
0 USD
CY2016Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
CY2016Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
6790 USD
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
6661 USD
CY2016Q1 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
3000 USD
CY2015Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
3000 USD
CY2016Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
388471 USD
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
0 USD
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1080601 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-748360 USD
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6789833 shares
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6789833 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6661000 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6661000 shares
CY2016Q1 us-gaap Sales Revenue Net
SalesRevenueNet
0 USD
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15000 USD
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
305571 USD
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
320571 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-320571 USD
CY2016Q1 us-gaap Interest Expense
InterestExpense
11670 USD
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
363003 USD
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6717767 shares
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Use of Estimates in Financial Statement Presentation -</b> The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q1 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
1000000 USD
CY2016Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.080 pure
CY2016Q1 mbrx Business Acquisitions Pro Forma Total Operating Expenses
BusinessAcquisitionsProFormaTotalOperatingExpenses
427815 USD
CY2016Q1 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-446406 USD
CY2016Q1 mbrx Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
-0.06
CY2016Q1 mbrx Business Acquisition Pro Forma Weighted Average Outstanding Common Shares Basic And Diluted
BusinessAcquisitionProFormaWeightedAverageOutstandingCommonSharesBasicAndDiluted
7717767 shares
CY2016Q1 mbrx Operating Loss Carryforwards Expiration Period
OperatingLossCarryforwardsExpirationPeriod
2035
CY2016Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
128833 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Expiration Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
2025-12-05
CY2016Q1 mbrx Debt Conversion Converted Instrument Common Stock Shares Issued Trading Restrictions Description
DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription
(a) begin 90 days after the initial closing of our IPO and until the one-year anniversary of the initial closing of the IPO, (a) the holder of the note will be able to sell 1% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily volume; (b) if the common stock price is over $7.00 per share for five consecutive trading days then the holder of the note can sell up to 3% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily volume; (c) if the common stock price is over $10.00 per share for five consecutive trading days then the holder of the note can sell up to an additional 5% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 7% of the daily volume; and (d) if the common stock price is over $14.00 per share then the holder of the note is not restricted from making any sales until such time as the common stock price falls back below $14.00 per share; and (b) thereafter, until the two-year anniversary of the initial closing of IPO, the holder of the note can sell on any trading day 10% of the daily volume; provided that if the common stock price is over $10.00 per share then the holder of the note is not restricted from making any sales until such time as the common stock falls back below $10.00 per share.
CY2016Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
386499 USD
CY2016Q1 mbrx Common Stock Lockup And Leakout Agreements Description
CommonStockLockupAndLeakoutAgreementsDescription
These shares are subject to the following lock-up agreement, from and after the later of six months after issuance or 90 days from the effective date of our IPO registration statement until the one-year anniversary thereof, (a) the shareholder can sell up to 10% of the purchased shares per month, subject to a maximum sale on any trading day of 8% of the daily volume of the common stock; (b) if the common stock price is over $7.00 per share for five consecutive trading days then the shareholder can sell up to 20% of the purchased shares per month, subject to a maximum sale on any trading day of 10% of the daily volume of the common stock; and (c) if the common stock price is over $12.00 per share then the shareholder is not restricted from making any sales until such time as the common stock price falls back below $12.00 per share.
CY2016Q1 mbrx Debt Instrument Convertible Number Of Common Shares
DebtInstrumentConvertibleNumberOfCommonShares
3749557 shares
CY2016Q1 mbrx Business Acquisition Pro Forma Current Assets
BusinessAcquisitionProFormaCurrentAssets
204737 USD
CY2016Q1 mbrx Business Acquisition Pro Forma Assets
BusinessAcquisitionProFormaAssets
7472357 USD
CY2016Q1 mbrx Business Acquisition Pro Forma Current Liabilities
BusinessAcquisitionProFormaCurrentLiabilities
1545697 USD
CY2016Q1 mbrx Business Acquisition Pro Forma Shareholders Equity
BusinessAcquisitionProFormaShareholdersEquity
5926660 USD
CY2016Q1 mbrx Business Acquisition Pro Forma Liabilities And Equity
BusinessAcquisitionProFormaLiabilitiesAndEquity
7472357 USD
CY2016Q1 mbrx Business Acquisition Pro Forma Non Current Assets
BusinessAcquisitionProFormaNonCurrentAssets
7267620 USD

Files In Submission

Name View Source Status
0001144204-16-108589-index-headers.html Edgar Link pending
0001144204-16-108589-index.html Edgar Link pending
0001144204-16-108589.txt Edgar Link pending
0001144204-16-108589-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mbrx-20160331.xml Edgar Link completed
mbrx-20160331.xsd Edgar Link pending
mbrx-20160331_cal.xml Edgar Link unprocessable
mbrx-20160331_def.xml Edgar Link unprocessable
mbrx-20160331_lab.xml Edgar Link unprocessable
mbrx-20160331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v442195_10q.htm Edgar Link pending
v442195_ex31-1.htm Edgar Link pending
v442195_ex31-2.htm Edgar Link pending
v442195_ex32-1.htm Edgar Link pending
v442195_ex32-2.htm Edgar Link pending